Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

Abstract: Provided herein are pharmaceutical compositions and methods useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

Abstract: In various aspects, the present disclosure provides methods, compositions, and kits for treating a target tissue with one or more active agents. In embodiments, delivering an active agent to a target tissue comprises administration of microbubbles and ultrasound.

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

Abstract: In various aspects, the present disclosure provides methods of preventing metastasis to bone in a subject with cancer, as well as compositions and kits for use in the same. In various aspects, the present disclosure provides methods of treating bone metastasis in a subject with cancer, as well as compositions and kits for use in the same. In embodiments, compositions comprise an MDA-7/IL-24 protein.

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

Abstract: In various aspects, the present disclosure provides polynucleotides encoding a fusion protein, as well as vectors, cells, and compositions comprising the same. In embodiments, the fusion protein includes an insulin signal peptide and an MDA-7/IL-24 protein. Methods of using the polynucleotides, vectors, cells, and compositions, such as in the treatment or prevention of cancer, are also provided.

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

Abstract: This invention discloses a method of modulating the survival and stemness of cancer stem cells (CSCs) by modulating the expression of MDA-9/Syntenin (SDCBP), which regulates multiple stemness genes, and controls survival of CSCs by activating the pathways, including without limitation NOTCH1. In one embodiment, the stemness genes that can be regulated by modulating expression or activity of MDA-9/Syntenin (SDCBP) includes, but are not limited to, ALDH1A1, AXL, CD44, DDR1, ID1, ITGB1, c-myc, Nanog, NOTCH, Oct4/POU5F1, Sox2, and STAT3. The invention also discloses a method of decreasing/inhibiting CSCs's tumorigenicity and a method of increasing survival of a subject with cancer by suppression of mda-9. This invention provides a method of inhibiting the growth of a cancer, and a method of determining the metastatic or angiogenic potential of a cancer. This invention further provides a method of screening for a candidate compound that modulate the expression or activities of MDA-9/Syntenin (SDCBP).

Abstract: The presently disclosed subject matter generally relates to genetic constructs and methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. In particular, the presently disclosed subject matter relates to tripartite cancer theranostic nucleic acid constructs that permit simultaneous cancer specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

Abstract: The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

Abstract: Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.

Abstract: Recombinant vectors in which expression of one or more elements (e.g. gene required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by an mda-9/syntenin (mda-9) cancer selective promoter are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, especially to visualize (image) and treat metastasis (including in rapid in vitro assays), and the transgenic mice are used to monitor cancer progression and/or the efficacy of candidate therapeutic agents in screening assays.

Abstract: Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by an mda-9/syntenin (mda-9) cancer selective promoter are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, especially to visualize (image) and treat metastasis (including in rapid in vitro assays), and the transgenic mice are used to monitor cancer progression and/or the efficacy of candidate therapeutic agents in screening assays.

Abstract: The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

Abstract: The presently disclosed subject matter generally relates to genetic constructs and methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. In particular, the presently disclosed subject matter relates to tripartite cancer theranostic nucleic acid constructs that permit simultaneous cancer specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.